Alteration of the gut microbiome in first-episode drug-naïve and chronic medicated schizophrenia correlate with regional brain volumesOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study examined whether the gut microbiome is altered in schizophrenia (SCZ) and whether such alterations relate to brain structure. Researchers used 16S rRNA gene sequencing of faecal samples to profile gut microbial composition. They also acquired T1-weighted structural MRI brain imaging data to test for correlations between microbial composition and structural brain signatures. The goal was to determine whether microbiome changes were linked to SCZ itself or to antipsychotic treatment.
Who was studied?
The study included 40 first-episode drug-naive schizophrenia (FSCZ) patients, 85 chronically antipsychotic-treated schizophrenia (TSCZ) patients, and 69 healthy controls (HCs). Faecal samples were collected from all participants for microbiome analysis. A subset also underwent structural brain MRI to allow correlation with microbial composition.
What were the most important findings?
TSCZ patients showed lower microbiome alpha-diversity compared to healthy controls, but this reduction was not seen in FSCZ patients. Both FSCZ and TSCZ patients had distinct changes in gut microbial composition compared to healthy controls, including alterations in Christensenellaceae, Enterobacteriaceae, Pasteurellaceae, and Turicibacteraceae at the family level, and Escherichia at the genus level. The abstract also indicates significant disturbances in gut microbial composition when comparing TSCZ to FSCZ patients directly.
What are the greatest implications of this study?
The findings suggest gut microbiome alterations, including in Christensenellaceae, are present from the earliest, treatment-naive stage of schizophrenia and are further altered with chronic antipsychotic treatment. Linking microbial composition to regional brain volumes supports a potential gut-brain connection in the pathogenesis of schizophrenia. This distinguishes disease-associated microbial changes from those attributable to medication, informing future work on the gut microbiome as a biomarker or target in psychiatric illness.